Table 3 Clinicopathological characteristics of BC cases
From: STAT3 gene polymorphisms and susceptibility to breast cancer in the Moroccan population
Clinicopathological characteristics | Cases n (%) N = 200 | Controls n (%) N = 200 | P value |
|---|---|---|---|
Age (mean ± SD) | 48.20 ± 10.52 | 48.21 ± 10.46 | 1 |
Menopause | |||
 Pre | 130 (65) | 136 (68) | 0.53 |
 Post | 70 (35) | 64 (32) |  |
Tumor histology | |||
 IDC | 149 (84.66) | – | – |
 ILC | 16 (9.09) |  |  |
 Medulary | 1 (0.57) |  |  |
 Other | 10 (5.68) |  |  |
SBR grading | |||
 I | 9 (5.14) | – | – |
 II | 102 (58.29) |  |  |
 III | 64 (36.57) |  |  |
Estrogen receptor (ER) | |||
 Pos | 143 (78.57) | – | – |
 Neg | 39 (21.43) |  |  |
Progesterone receptor (PR) | |||
 Pos | 110 (68.32) | – | – |
 Neg | 51 (31.68) |  |  |
Human epidermal growth factor 2 (HER2) receptor | |||
 Pos | 46 (29.11) | – | – |
 Neg | 112 (70.89) |  |  |
Immuno-histochemical (IHC) subtypes | |||
 Luminal A | 85 (54.49) | – | – |
 Luminal B | 35 (22.44) |  |  |
 Triple neg | 26 (16.66) |  |  |
 HER2/neu | 10 (6.41) |  |  |